SG11201912186SA - Composition for injection - Google Patents

Composition for injection

Info

Publication number
SG11201912186SA
SG11201912186SA SG11201912186SA SG11201912186SA SG11201912186SA SG 11201912186S A SG11201912186S A SG 11201912186SA SG 11201912186S A SG11201912186S A SG 11201912186SA SG 11201912186S A SG11201912186S A SG 11201912186SA SG 11201912186S A SG11201912186S A SG 11201912186SA
Authority
SG
Singapore
Prior art keywords
injection
composition
Prior art date
Application number
SG11201912186SA
Other languages
English (en)
Inventor
Hyo Jin Kim
Sung Jun Kim
Min Kyoung Lee
Sung Ah Lee
Mi Young Yoon
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of SG11201912186SA publication Critical patent/SG11201912186SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
SG11201912186SA 2017-07-07 2018-07-06 Composition for injection SG11201912186SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170086696A KR102262743B1 (ko) 2017-07-07 2017-07-07 주사용 조성물
PCT/KR2018/007693 WO2019009661A1 (en) 2017-07-07 2018-07-06 SKIN INJECTION COMPOSITION

Publications (1)

Publication Number Publication Date
SG11201912186SA true SG11201912186SA (en) 2020-01-30

Family

ID=64951074

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912186SA SG11201912186SA (en) 2017-07-07 2018-07-06 Composition for injection

Country Status (12)

Country Link
US (1) US10828253B2 (ko)
EP (1) EP3648739B8 (ko)
JP (1) JP6882538B2 (ko)
KR (1) KR102262743B1 (ko)
CN (1) CN110876259B (ko)
BR (1) BR112020000174A2 (ko)
EA (1) EA202090040A1 (ko)
ES (1) ES2940443T3 (ko)
PH (1) PH12019502868A1 (ko)
SG (1) SG11201912186SA (ko)
UA (1) UA124818C2 (ko)
WO (1) WO2019009661A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101829706B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR102648314B1 (ko) 2021-12-08 2024-03-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도
WO2023182877A1 (ko) * 2022-03-24 2023-09-28 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836541A (en) * 1953-12-04 1958-05-27 Sterling Drug Inc Mannitol stabilized morphinepapaverine composition
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US20050255161A1 (en) * 2004-05-10 2005-11-17 Servet Buyuktimkin Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
BRPI0620081B8 (pt) * 2005-12-19 2021-05-25 Pfizer composto e composição farmacêutica.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2409699B1 (en) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
JP6250646B2 (ja) * 2012-05-25 2017-12-20 ノバルティス アーゲー 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤
KR20160144927A (ko) 2015-06-08 2016-12-19 씨제이헬스케어 주식회사 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도
KR101829685B1 (ko) * 2016-07-28 2018-02-19 씨제이헬스케어 주식회사 안정성 및 용해도가 개선된 주사용 조성물
CN106377497A (zh) * 2016-09-05 2017-02-08 雄九(上海)医药技术股份有限公司 含有辅酶q10的注射剂组合物及其制备方法
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물

Also Published As

Publication number Publication date
WO2019009661A1 (en) 2019-01-10
JP6882538B2 (ja) 2021-06-02
EP3648739A1 (en) 2020-05-13
EP3648739A4 (en) 2021-04-14
UA124818C2 (uk) 2021-11-24
KR20190005674A (ko) 2019-01-16
JP2020525516A (ja) 2020-08-27
CN110876259B (zh) 2023-08-01
KR102262743B1 (ko) 2021-06-09
CN110876259A (zh) 2020-03-10
PH12019502868A1 (en) 2020-10-05
US10828253B2 (en) 2020-11-10
EP3648739B8 (en) 2023-03-01
EA202090040A1 (ru) 2020-05-27
US20200146974A1 (en) 2020-05-14
ES2940443T3 (es) 2023-05-08
EP3648739B1 (en) 2023-01-25
BR112020000174A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
ZA202002723B (en) Composition
GB201703455D0 (en) Composition
GB2562466B (en) Composition
GB201719139D0 (en) Composition
SG11201912186SA (en) Composition for injection
GB201700504D0 (en) Composition
GB201713636D0 (en) Composition
GB201712151D0 (en) Composition
GB201600075D0 (en) Immunogenci composition
GB201707238D0 (en) Composition
GB201702833D0 (en) Composition
GB201816988D0 (en) Composition
ZA201804584B (en) Fuel composition
RS64676B1 (sr) Probiotska kompozicija
GB201721674D0 (en) Composition
GB201718871D0 (en) Composition
GB201715135D0 (en) Composition
GB201711446D0 (en) Composition
GB201707920D0 (en) Composition
ZA201904385B (en) Composition
HUE063642T2 (hu) Probiotikus készítmény
GB201721675D0 (en) Composition
GB201719763D0 (en) Composition
GB201719456D0 (en) Composition
GB201717637D0 (en) Composition